Psoriatic Arthritis

Biomarkers for evaluating psoriatic arthritis (PsA)

Psoriatic arthritis is a chronic inflammatory disease that develops in up to 30% of patients with psoriasis. This is therefore a disease characterized by remodeling of several tissues including, skin, bone, synovium, and cartilage.

Tissue-specific biomarkers, quantifying and monitoring damage of these tissues and immune-cell activity are key advantages when understanding the disease mechanisms and complexity in psoriatic arthritis, and lead to targeted successful treatments.

Did you know?

Despite the recent years development of effective drugs for PsA, there is still several aspects of unmet needs. These needs can be addressed by utilizing biomarkers to improve early diagnosis, prognosis, management of PsA patients, and identification of novel therapeutic targets.

Publications

Nordic ProteinFingerPrint Technology™ biomarkers in psoriatic arthritis

Our rheumatology biomarker panels offer extracellular matrix-based-based biomarkers, which are fundamentally more different and more specific compared to what’s offered by omics providers. Our technology provides valuable insights into tissue formation, degradation, and resolution, that offer a deeper understanding of pathological processes related to skin and joint diseases. At the same time, proteomics providers’ wide-range arrays may not offer the same level of specificity.

Tissue remodeling and immune cell activity are key features of psoriatic arthritis. Quantifying disease activity and remodeling in psoriatic arthritis can provide a unique insight into structural and functional changes in the disease pathogenesis. In addition, one of the key features of the biomarkers is the ability to monitor the disease activity, pharmacodynamic effects, and identification of disease endotypes.

Browse our rheumatology biomarkers

Biomarkers associated with psoriatic disease and treatment response in psoriatic arthritis

A balanced extracellular matrix (ECM) is necessary to preserve skin and joint integrity and tissue homeostasis. Type I collagen is the major protein in the skin and bones and are remodeled in psoriatic disease. Biomarkers able to separate between psoriasis and psoriatic arthritis, could identify patients in risk of progressing from psoriasis to psoriatic arthritis.

The biomarker C1M, is a biomarker measuring type I collagen degradation by matrix metalloproteinases (MMPs), can separate between patients with psoriasis and psoriatic arthritis (Figure 1A). The same biomarker is also a pharmacodynamic biomarker, suppressed by treatment with Guselkumab (IL-23p19 mAb) from the DISCOVER-2 trial (Figure 1B).

Learn more about our technology

The Nordic ProteinFingerPrint Technology™ in rheumatic disorders

Unsure about how our technology can benefit your clinical trial in rheumatic disorder? Watch this short video and get an understanding of the benefit you gain from our biomarkers .

About psoriatic arthritis (PsA)

  • Psoriatic arthritis (PsA) is a chronic, immune-mediated inflammatory disease that affects the joints and connective tissues, occurring in up to 30% of individuals with psoriasis. It typically develops in early to mid-adulthood and is a lifelong condition.

    Diagnosis of PsA is based on clinical examination, medical history, and imaging techniques such as X-rays and MRI. Treatment options depend on disease severity and may include nonsteroidal anti-inflammatory drugs (NSAIDs), conventional disease-modifying antirheumatic drugs (DMARDs), biologics, and targeted synthetic DMARDs.

  • PsA is characterized by joint pain, stiffness, and swelling, often affecting the fingers, toes, lower back, and larger joints. The disease can lead to progressive joint damage, causing disability if left untreated.

  • PsA involves chronic inflammation that affects both the joints and surrounding connective tissues, leading to structural damage over time.

     

    Collagens and other extracellular matrix components play a key role in joint integrity and remodeling. Protein fingerprint biomarkers can quantify joint tissue turnover through a simple serum sample, serving as a liquid biopsy to assess disease activity and progression

Get in touch

Are you interested in exploring collaboration possibilities?
Enter your information in the form and a representative will contact you shortly.
+45 4452 5252 Contact us via email!

    Nordic Bioscience’s assays and services are research use only products and services and do not qualify for medical or diagnostic purposes.

    Upcoming events

    No upcoming events

    News, events, and other resources

    Discover Nordic Bioscience